Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.04 USD
-0.33 (-13.92%)
Updated May 8, 2024 04:00 PM ET
After-Market: $2.05 +0.01 (0.49%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
ESPR 2.04 -0.33(-13.92%)
Will ESPR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ESPR
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
Other News for ESPR
Analysts Have Conflicting Sentiments on These Healthcare Companies: Henry Schein (HSIC) and Esperion (ESPR)
Esperion Gains Buy Rating on Strong Sales Growth and Strategic Progress
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)
Esperion’s Market Uncertainty Justifies Hold Rating Despite Promising Early Results
Esperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...